TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome

Oncotarget

Volumn 6, Issue 27, 2015, Pages 23708-23719

  Chen, Yu ^a   Guo, Yongfei ^a   Yang, Haisong ^a   Shi, Guodong ^a   Xu, Guohua ^a   Shi, Jiangang ^a   Yin, Na ^b   Chen, Deyu ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

EMT; Osteosarcoma; P53; TGF ; TRIM66

Indexed keywords

PEPTIDES AND PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRIPARTITE MOTIF CONTAINING 66 PROTEIN; UNCLASSIFIED DRUG; CASPASE 7; CASPASE 9; PROTEIN P53; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TRIM66 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL MOTION; DRUG SCREENING; GENETICS; LUNG TUMOR; METABOLISM; MORTALITY; NUDE MOUSE; ONCOGENE; PATHOLOGY; RNA INTERFERENCE; SECONDARY; TUMOR CELL LINE; TUMOR INVASION; TUMOR RECURRENCE;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CASPASE 7; CASPASE 9; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; ONCOGENES; OSTEOSARCOMA; RETROSPECTIVE STUDIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943424638     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4291     Document Type: Article

References (35)

1. Hatakeyama S. TRIM proteins and cancer. Nat Rev Cancer. 2011;11:792-804.
2. Khetchoumian K, Teletin M, Mark M, Lerouge T, Cervino M, Oulad-Abdelghani M, Chambon P, Losson R. TIF1delta, a novel HP1-interacting member of the transcriptional intermediary factor 1(TIF1) family expressed by elongating spermatids. J Biol Chem. 2004;279:48329-48341.
3. Lee M-H, Yang H-Y. Contributions in the domain of cancer research:Review Negative regulators of cyclin-dependent kinases and their roles in cancers. Cellular and Molecular Life Sciences CMLS. 2001;58:1907-1922.
4. Gandini D, De Angeli C, Aguiari G, Manzati E, Lanza F, Pandolfi PP, Cuneo A, Castoldi GL, del Senno L. Preferential expression of the transcription coactivator HTIF1alpha gene in acute myeloid leukemia and MDSrelated AML. Leukemia. 2002;16:886-893.
5. Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, Aronow B, Gozani O, Fischle W, Hung MC, Patel DJ, Barton MC. TRIM24 links a non-canonical histone signature to breast cancer. Nature. 2010;468:927-932.
6. Chambon M, Orsetti B, Berthe ML, Bascoul-Mollevi C, Rodriguez C, Duong V, Gleizes M, Thenot S, Bibeau F, Theillet C, Cavailles V. Prognostic significance of TRIM24/TIF-1alpha gene expression in breast cancer. Am J Pathol. 2011;178:1461-1469.
7. Aucagne R, Droin N, Paggetti J, Lagrange B, Largeot A, Hammann A, Bataille A, Martin L, Yan KP, Fenaux P, Losson R, Solary E, Bastie JN, Delva L. Transcription intermediary factor 1gamma is a tumor suppressor in mouse and human chronic myelomonocytic leukemia. J Clin Invest. 2011;121:2361-2370.
8. Yokoe T, Toiyama Y, Okugawa Y, Tanaka K, Ohi M, Inoue Y, Mohri Y, Miki C, Kusunoki M. KAP1 is associated with peritoneal carcinomatosis in gastric cancer. Ann Surg Oncol. 2010;17:821-828.
9. Suzuki T, Urano T, Tsukui T, Horie-Inoue K, Moriya T, Ishida T, Muramatsu M, Ouchi Y, Sasano H, Inoue S. Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clin Cancer Res. 2005; 11:6148-6154.
10. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma:National Cancer Data Base Report. Clin Orthop Relat Res. 2007;459:40-47.
11. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma, Pediatric and Adolescent Osteosarcoma. Springer. 2010; pp. 3-13.
12. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027.
13. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy:a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
14. Rytting M, Pearson P, Raymond AK, Ayala A, Murray J, Yasko AW, Johnson M, Jaffe N. Osteosarcoma in preadolescent patients. Clin Orthop Relat Res. 2000; 373:39-50.
15. Sakamoto A, Iwamoto Y. Current status and perspectives regarding the treatment of osteosarcoma:chemotherapy, Reviews on recent clinical trials. 2008;3:228.
16. Hu Y, Chen HY, Yu CY, Xu J, Wang JL, Qian J, Zhang X, Fang JY. A long non-coding RNA signature to improve prognosis prediction of colorectal cancer. Oncotarget. 2014; 5:2230-2242.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES. Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545-15550.
18. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC, Wang SB, Wang YZ, Yang Y, Yang N, Zhou WP, Yang GS, Sun SH. A long noncoding RNA activated by TGF-beta promotes the invasionmetastasis cascade in hepatocellular carcinoma. Cancer Cell. 2014;25:666-681.
19. Sun T, Du W, Xiong H, Yu Y, Weng Y, Ren L, Zhao H, Wang Y, Chen Y, Xu J, Xiang Y, Qin W, Cao W, Zou W, Chen H, Hong J, Fang JY. TMEFF2 deregulation contributes to gastric carcinogenesis and indicates poor survival outcome. Clin Cancer Res. 2014; 20:4689-4704.
20. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, Orntoft TF. Gene expression in the urinary bladder:a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 2004;64:4040-4048.
21. Glebov OK, Rodriguez LM, Soballe P, DeNobile J, Cliatt J, Nakahara K, Kirsch IR. Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa. Cancer Epidemiol Biomarkers Prev. 2006;15:2253-2262.
22. Hawthorn L, Stein L, Panzarella J, Loewen GM, Baumann H. Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung. Lung Cancer. 2006;53:129-142.
23. Kosaka Y, Inoue H, Ohmachi T, Yokoe T, Matsumoto T, Mimori K, Tanaka F, Watanabe M, Mori M. Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol. 2007; 14:2543-2549.
24. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr, Pecorelli S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004; 112:14-25.
25. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22:9030-9040.
26. Shen Y, White E. p53-dependent apoptosis pathways. Adv Cancer Res. 2001;82:55-84.
27. Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, Bergmann A, Johnson RL, Barton MC. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A. 2009;106:11612-11616.
28. Wang C, Ivanov A, Chen L, Fredericks WJ, Seto E, Rauscher FJ, 3rd, Chen J. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. Embo j. 2005;24:3279-3290.
29. Wang C, Rauscher FJ, 3rd, Cress WD, Chen J. Regulation of E2F1 function by the nuclear corepressor KAP1. J Biol Chem. 2007;282:29902-29909.
30. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
31. Yang G, Yuan J, Li K. EMT transcription factors:implication in osteosarcoma. Med Oncol. 2013;30:1-5.
32. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151-166.
33. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131-142.
34. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350-1358.
35. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J. Hematopoiesis controlled by distinct TIF1γand Smad4 branches of the TGFβpathway. Cell. 2006;125:929-941.